BAAM
KRTX

Baker Avenue Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Baker Avenue Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6
Closed -$1.01K – 1593
2023
Q3 		$1.01K Buy
6
+1
+20% +$188 ﹤0.01% 1270
2023
Q2 		$1.08K Hold
5
– – ﹤0.01% 1149
2023
Q1 		$908 Hold
5
– – ﹤0.01% 1216
2022
Q4 		$983 Buy
+5
New +$1.07K ﹤0.01% 1108

Other funds holding KRTX

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Baker Avenue Asset Management's KRTX Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023, closing a stake of 6 shares — an estimated $1.01K sold.

Baker Avenue Asset Management first reported a position in KRTX in Q4 2022 and held it in 4 quarters. The position peaked at $1.08K in Q2 2023. 328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 6 Karuna Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $1.01K.
  • Baker Avenue Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
  • Baker Avenue Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $1.08K in Q2 2023.
  • 328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.